Medical Device | February 28, 2022
Europe clears blood test to predict Alzheimer’s disease
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
100% efficacy against severe Covid-19 disease and hospitalizations
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Darolutamide is developed jointly by Bayer and Orion Corporation
On track to complete the BLA submission in the first half of 2022
Cysoni is a bionic device that paces the heart with real-time respiratory modulation. The innovation stems from the idea that heart rate increases and decreases with each breath in normal physiology, termed ‘respiratory sinus arrhythmia’ (RSA)
Subscribe To Our Newsletter & Stay Updated
